NASDAQ:IMMP
Immutep Ltd Stock News
$2.96
+0.0400 (+1.37%)
At Close: May 17, 2024
Immutep's Lead Candidate To Be Tested In Combination With Keytruda In Second Head & Neck Cancer Study
09:15am, Tuesday, 16'th Mar 2021
Immutep (NASDAQ: IMMP) announces a second clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). Under the agreement, Immutep will conduct a new Phase 2B clinical tri
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer
08:00am, Tuesday, 16'th Mar 2021
Sydney, AUSTRALIA, March 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments f
Immutep Expands Part B of TACTI-002 Study
08:00am, Friday, 05'th Mar 2021
Follows positive efficacy and safety review Follows positive efficacy and safety review
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
05:40pm, Thursday, 21'st Jan 2021
Immutep's Collaboration and Exclusive License with GSK Remains in Place Immutep's Collaboration and Exclusive License with GSK Remains in Place
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
07:04pm, Wednesday, 06'th Jan 2021
Sydney, AUSTRALIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is p
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
04:54pm, Tuesday, 29'th Dec 2020
Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for
Shares of Startup Biotechs Soar on Cancer Study Results
06:00pm, Monday, 28'th Dec 2020
Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching fo
Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day
03:15pm, Sunday, 13'th Dec 2020
JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech reporte
IMMP Stock: Why Immutep Stock Is Up 225% So Far Today
12:26pm, Thursday, 10'th Dec 2020
Shares of IMMP stock are taking off on Thursday after the firm's China-based partner announced a new breast cancer treatment trial in 2021. The post IMMP Stock: Why Immutep Stock Is Up 225% So Far Tod
Why Greenwich LifeSciences, Immutep And Tenet Are Trading Higher Today
12:05pm, Thursday, 10'th Dec 2020
Immutep (NASDAQ: IMMP) shares are trading higher on Thursday after the company reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study in meta
Immutep shares soar 190% on positive results in trial of breast cancer treatment
11:31am, Thursday, 10'th Dec 2020
Shares of Immumetp Ltd., an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer.
Immutep's Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study
05:53pm, Wednesday, 09'th Dec 2020
Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is
Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pl
Immutep Announces Expansion of TACTI-002 Collaboration Trial
06:19pm, Wednesday, 18'th Nov 2020
SYDNEY, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“efti�
